argenex SE (NASDAQ:ARGX) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Moderate Buy consensus: 24 analysts rate argenex (ARGX) at an average recommendation of "Moderate Buy" (18 buy, 4 hold, 2 strong buy) with a 1‑year average price target of $1,016.22.
• Valuation and price action: ARGX opened at $807.55 (market cap ~$50.22B) and trades at a P/E of 41.37, with a 1‑year range of $510.05–$934.62, implying analyst targets suggest upside from current levels.
• Fundamentals and ownership: The company reported quarterly EPS of $8.02, a 30.42% net margin and 38.51% ROE, analysts expect ~24.63 EPS for the fiscal year, institutional investors own ~60.3% of the stock, and its lead product is the FcRn antagonist Vyvgart.

Shares of argenex SE (NASDAQ:ARGX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the twenty-four analysts that are covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation, eighteen have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $1,016.2222.

A number of equities research analysts have recently commented on ARGX shares. Wedbush reiterated an "outperform" rating and set a $1,000.00 price objective on shares of argenex in a research report on Monday, March 9th. Zacks Research upgraded argenex from a "strong sell" rating to a "hold" rating in a research report on Friday, February 20th. Deutsche Bank Aktiengesellschaft upgraded argenex from a "hold" rating to a "buy" rating in a research report on Tuesday, March 10th. Oppenheimer cut their price objective on argenex from $1,060.00 to $1,014.00 and set an "outperform" rating for the company in a research report on Thursday, April 2nd. Finally, Guggenheim cut their price objective on argenex from $1,160.00 to $1,120.00 and set a "buy" rating for the company in a research report on Friday, February 27th.

argenex Price Performance

ARGX opened at $807.55 on Thursday. The company has a market capitalization of $50.22 billion, a price-to-earnings ratio of 41.37, a price-to-earnings-growth ratio of 1.31 and a beta of 0.46. argenex has a 1-year low of $510.05 and a 1-year high of $934.62. The business has a 50 day moving average price of $756.94 and a two-hundred day moving average price of $817.94.

argenex (NASDAQ:ARGX - Get Free Report) last released its earnings results on Saturday, February 14th. The company reported $8.02 earnings per share for the quarter. argenex had a return on equity of 38.51% and a net margin of 30.42%. Equities analysts expect that argenex will post 24.63 EPS for the current fiscal year.

Institutional Investors Weigh In On argenex

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Oppenheimer & Co. Inc. lifted its holdings in shares of argenex by 2.8% in the fourth quarter. Oppenheimer & Co. Inc. now owns 442 shares of the company's stock valued at $372,000 after purchasing an additional 12 shares in the last quarter. Valeo Financial Advisors LLC lifted its holdings in shares of argenex by 0.9% in the fourth quarter. Valeo Financial Advisors LLC now owns 1,372 shares of the company's stock valued at $1,153,000 after purchasing an additional 12 shares in the last quarter. CI Investments Inc. lifted its holdings in shares of argenex by 2.6% in the fourth quarter. CI Investments Inc. now owns 469 shares of the company's stock valued at $394,000 after purchasing an additional 12 shares in the last quarter. Sound View Wealth Advisors Group LLC lifted its holdings in shares of argenex by 3.4% in the third quarter. Sound View Wealth Advisors Group LLC now owns 396 shares of the company's stock valued at $292,000 after purchasing an additional 13 shares in the last quarter. Finally, Allworth Financial LP lifted its holdings in shares of argenex by 12.7% in the fourth quarter. Allworth Financial LP now owns 115 shares of the company's stock valued at $97,000 after purchasing an additional 13 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company's stock.

argenex Company Profile

argenx NASDAQ: ARGX is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx's research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company's lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.